Last reviewed 2026-04-20 · How we verify

Psorcon (DIFLORASONE DIACETATE)

Pfizer · FDA-approved approved Small molecule Quality 39/100

Psorcon (generic name: DIFLORASONE DIACETATE) is a Corticosteroid Small molecule drug developed by Pfizer. It is currently FDA-approved (first approved 1977) for Corticosteroid-responsive dermatoses.

Psorcon (DIFLORASONE DIACETATE) is a corticosteroid medication that targets the glucocorticoid receptor. Originally developed by Pharmacia and Upjohn, it is now owned by Pfizer. Psorcon is used to treat various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. It is a small molecule corticosteroid that has been FDA-approved since 1977 and is currently available as a generic medication. Psorcon is off-patent and has multiple generic manufacturers.

At a glance

Generic name	DIFLORASONE DIACETATE
Sponsor	Pfizer
Drug class	Corticosteroid
Target	Glucocorticoid receptor
Modality	Small molecule
Therapeutic area	Oncology
Phase	FDA-approved
First approval	1977

Approved indications

Corticosteroid-responsive dermatoses

Common side effects

Skin atrophy
Secondary infection
Maceration of the skin
Miliaria
Striae
Allergic contact dermatitis
Perioral dermatitis
Hypopigmentation
Acneiform eruptions
Hypertrichosis
Folliculitis
Dryness

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Psorcon CI brief — competitive landscape report
Psorcon updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Psorcon

What is Psorcon?

Psorcon (DIFLORASONE DIACETATE) is a Corticosteroid drug developed by Pfizer, indicated for Corticosteroid-responsive dermatoses.

What is Psorcon used for?

Psorcon is indicated for Corticosteroid-responsive dermatoses.

Who makes Psorcon?

Psorcon is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Psorcon?

DIFLORASONE DIACETATE is the generic (nonproprietary) name of Psorcon.

What drug class is Psorcon in?

Psorcon belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

When was Psorcon approved?

Psorcon was first approved on 1977.

What development phase is Psorcon in?

Psorcon is FDA-approved (marketed).

What are the side effects of Psorcon?

Common side effects of Psorcon include Skin atrophy, Secondary infection, Maceration of the skin, Miliaria, Striae, Allergic contact dermatitis.

What does Psorcon target?

Psorcon targets Glucocorticoid receptor and is a Corticosteroid.

Drug class: All Corticosteroid drugs
Target: All drugs targeting Glucocorticoid receptor
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Corticosteroid-responsive dermatoses

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing